Nanoscope Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Nanoscope Therapeutics's estimated annual revenue is currently $2.6M per year.
- Nanoscope Therapeutics's estimated revenue per employee is $77,500
- Nanoscope Therapeutics's total funding is $13M.
Employee Data
- Nanoscope Therapeutics has 34 Employees.
- Nanoscope Therapeutics grew their employee count by 26% last year.
Nanoscope Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder & President | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | VP Quality | Reveal Email/Phone |
5 | VP Regulatory Affairs | Reveal Email/Phone |
6 | SVP, Regulatory Affairs | Reveal Email/Phone |
7 | VP Global Research & Development | Reveal Email/Phone |
8 | VP Clinical Operations | Reveal Email/Phone |
9 | Director IP & Project Management | Reveal Email/Phone |
10 | Director Non-clinical Development | Reveal Email/Phone |
Nanoscope Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Nanoscope Therapeutics?
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
keywords:N/A
$13M
Total Funding
34
Number of Employees
$2.6M
Revenue (est)
26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nanoscope Therapeutics News
About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering...
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, has appointed Aaron...
Nanoscope's Multi-Characteristic Opsin (MCO) gene therapy platform is designed to restore vision in patients blinded by retinal degenerative...
Other Companies in Bedford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.9M | 34 | 42% | N/A |
#2 | $7.3M | 34 | -15% | N/A |
#3 | $3.9M | 34 | N/A | N/A |
#4 | $7.3M | 37 | 0% | N/A |
#5 | $6.2M | 37 | -3% | N/A |